Pag-aaralan na raw ng Health Technology Assessment Council (HTAC) ang mga bagong ebidensya sa anti-Ebola drug na remdesivir bilang treatment sa COVID-19.
Ayon sa Department of Health (DOH), magkakaroon ng independent assessment ang HTAC kasunod ng ulat na inaprubahan ng Food and Drug Administration sa Estados Unidso ang remdesivir bilang panggamot sa coronavirus patients.
“HTAC here in the country will also conduct an independent assessment of all available data to come up with a good recommendation.”
Batay sa news release ng US FDA, aprubado lang ang remdesivir bilang treatment na gamot sa matatanda at pediatric patients na 12-anyos pababa, na may timbang na 40-kilograms, at inirerekomendang ma-admit sa ospital.
“This approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020… Clinical trials assessing the safety and efficacy of Veklury in this pediatric patient population are ongoing.”
Sa ngayon, mananatili raw munang available ang gamot sa Pilipinas para sa compassionate use, ayon sa DOH.
“In the meantime, Remdesivir will continue to be available for compassionate use according to PSMID (Philippine Society for Microbiology and Infectious Diseases, Inc.) guidelines until these are modified accordingly.”
Bukod sa compassionate use, ginagamit din ang remdesivir sa bansa bilang gamot sa Solidarity Therapeutic Trials ng World Health Organization.
